Arbor Biotechnologies

Arbor Biotechnologies is a private, pre-revenue biotech firm pioneering next-generation CRISPR-based gene editing technologies. The company has built a wholly owned portfolio of proprietary DNA editors capable of addressing over 90% of the human genome, which it is leveraging to develop bespoke genetic medicines. With a lead program, ABO-101, advancing through regulatory milestones and strategic partnerships with Vertex Pharmaceuticals, Chiesi Group, and others, Arbor is positioned to pursue functional cures for rare and common diseases. The company is backed by significant venture capital, including a $215M Series B and a $74.9M Series C financing.

A diverse toolbox of novel, programmable DNA editors (including Cas12i2, Cas13d, and transposase systems) capable of addressing >90% of the human genome for bespoke genetic medicine development.

Arbor competes in the gene editing therapeutics space with public leaders like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics, as well as large pharma. Its differentiation lies in its diverse, proprietary portfolio of next-generation editors, offering potential advantages in specificity, size, or functionality over standard Cas9 systems.